leadf
logo-loader
viewPhagoMed Biopharma

PhagoMed looks to raise around $18M to scale up its bacterial infections treatment

PhagoMed Biopharma GmbH CEO Alexander Belcredi spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The Austria-based biotech's pipeline is focused on treating biofilm-forming bacterial infections, which are all in preclinical development. The company specializes in fighting multi-resistant bacteria, where multiple antibiotics have become ineffective.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Iofina says 'our business has been strong' reporting record revenue and...

Iofina PLC (AIM:IOF, OTC:IOFNF, FRA:IF7) (AIM:IOF, OTC:IOFNF, FRA:IF7) Tom Becker joins Proactive London to explain what drove their record revenue and profit in the first half.  Debt also fell in the first half of the year despite production outages caused by extreme weather and reduced...

1 day, 3 hours ago

2 min read